No. | Age (years) | Gender | Body Weight (kg) | Dose (mg/kg) | Ross Score/NYHA Class |
---|---|---|---|---|---|
1 | 0.12 | Female | 3.1 | 0.09 | 3 |
2 | 0.13 | Male | 4 | 0.09 | 6 |
3 | 0.15 | Male | 3.9 | 0.09 | 3 |
4 | 0.5 | Female | 5.2 | 0.09 | 8 |
5 | 0.75 | Male | 8 | 0.09 | 3 |
6 | 1.25 | Male | 10.1 | 0.09 | 3 |
7 | 1.5 | Male | 9.5 | 0.09 | 10 |
8 | 3.5 | Female | 13.1 | 0.09 | 3 |
9 | 5.5 | Male | 20.2 | 0.09 | 3 |
10 | 7.5 | Male | 24.3 | 0.09 | 5 |
11 | 8.25 | Male | 25.8 | 0.09 | 7 |
12 | 11.6 | Female | 34.3 | 0.09 | 4 |
13 | 11.8 | Male | 39 | 0.09 | 2 |
14 | 17.5 | Male | 56 | 0.09 | NYHA II |
15 | 17.8 | Male | 61 | 0.09 | NYHA III |
16 | 19.3a | Male | 98.2 | 0.09 | NYHA III |
Mean | 6.7 | 26 | — | — | |
S.D. | 6.72 | 25.6 | — | — |
All patients were diagnosed with heart failure and were participants in the same clinical trial (Behn, 2001).
↵a Patient out of the pediatric age range according to guidelines set by World Health Organization.